GT Biopharma (GTBP) Projected to Post Quarterly Earnings on Tuesday

GT Biopharma (NASDAQ:GTBP) is projected to issue its quarterly earnings data before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($1.55) per share for the quarter.

GT Biopharma Price Performance

GT Biopharma stock opened at $2.50 on Monday. The business has a fifty day moving average price of $2.29 and a 200-day moving average price of $2.50. GT Biopharma has a 1-year low of $1.72 and a 1-year high of $10.66. The stock has a market capitalization of $6.34 million, a price-to-earnings ratio of -0.36 and a beta of 0.59.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Roth Mkm started coverage on GT Biopharma in a research note on Monday, December 2nd. They set a “buy” rating and a $11.00 price target on the stock. Roth Capital raised shares of GT Biopharma to a “strong-buy” rating in a research report on Monday, December 2nd.

GT Biopharma Company Profile

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.